Antiretroviral therapy in primary HIV

Abstract

Initiation of antiretroviral therapy during primary HIV-1 infection may well redefine the course of the disease by controlling the burst of viral replication and subsequent immune dysfunction. At present, treatment of acute primary HIV-1 should remain largely in the domain of clinical investigation. There are significant problems in providing constant vigilance to medication and subsequent viral suppression. Only clinical trials can define the relative benefit of initiating antiretrovirals during this stage of infection.